doi: 10.1161/hs0102.101478
(Stroke. 2002;33:122.)
© 2002 American Heart Association, Inc.
Original Contributions |
Clomethiazole Acute Stroke Study in Ischemic Stroke (CLASS-I)
Final Results
From the Departments of Neurosciences, UCSD School of Medicine, and Neurology, Veterans Administration Medical Center (P.L.), San Diego, Calif; Department of Neurology (A.S.), University of Alberta, Edmonton, Alberta; Ocala Medical Center (K.N.), Ocala, Fla; Neurology Group of Bergen County (K.L.), Ridgewood, NJ; Mercy General Hospital (R.A.), Sacramento, Calif; Department of Neurology, Royal University Hospital (A.R.), Saskatoon, Saskatchewan; University of Pittsburgh Medical Center Stroke Center (L.W.), Pittsburgh, Pa; AstraZeneca (T.A., L.C., T.O.), Södertälje, Sweden, and AstraZeneca LP (E.S-G.), Wilmington, Del.
Correspondence to Dr Patrick Lyden, OPC Third Floor, Suite 3, 200 W Arbor Dr, San Diego, CA 92103–8466. E-mail plyden{at}ucsd.edu
Background and Purpose— A previous trial (the Clomethiazole Acute Stroke Study) generated the hypothesis that clomethiazole is effective in patients with a major ischemic stroke (total anterior circulation syndrome), and this was tested in the present study.
Methods— A total of 1198 patients with major ischemic stroke and a combination of limb weakness, higher cortical dysfunction, and visual field deficits were randomly assigned to clomethiazole (68 mg/kg IV over 24 hours) or placebo. The study drug was initiated within 12 hours of symptom onset. Functional outcome and neurological recovery were assessed at days 7, 30, and 90, with the proportion of patients with a Barthel Index 
60 at last follow-up as the primary outcome measure.
Results— The patients were randomly assigned equally, and the two treatment groups were well matched for baseline characteristics, including stroke severity (mean National Institutes of Health Stroke Scale score 16.9±5.2). Ninety-six percent were classified as total anterior circulation syndrome. The proportion of patients reaching a Barthel Index score of 60 was 42% in the clomethiazole-treated group and 46% in the placebo-treated group (odds ratio, 0.81; 95% CI, 0.62 to 1.05; P=0.11). There was no evidence of efficacy on any secondary outcome variables (modified Rankin Score, National Institutes of Health Stroke Scale, Scandinavian Stroke Scale, and 30-day CT infarct volumes) compared with placebo. Subgroup analysis showed a similar lack of treatment effect in patients treated early (<6 hours) and in those treated later (6 to 12 hours). Somnolence was an expected pharmacological effect of clomethiazole, and this occurred during treatment as an adverse event in half of the patients randomly assigned to study drug.
Conclusions— The target population was selected, and sufficient drug was given to produce the expected pharmacological effect in the brain. Clomethiazole does not improve outcome in patients with major ischemic stroke.
Editorial Comment
Final Results
Royal Perth Hospital, Department of Medicine, University of Western Australia, Perth, Western Australia
This article has been cited by other articles:
 |
|
 |
|
  P. Mandava and T. A. Kent A Method to Determine Stroke Trial Success Using Multidimensional Pooled Control Functions Stroke, May 1, 2009; 40(5): 1803 - 1810. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. W. Wasiewski To Phase 3 or Not to Phase 3? Stroke, May 1, 2009; 40(5): 1553 - 1554. [Full Text] [PDF]
|
|
|
|
|
|
M. Ali, P. M.W. Bath, J. Curram, S. M. Davis, H.-C. Diener, G. A. Donnan, M. Fisher, B. A. Gregson, J. Grotta, W. Hacke, et al. The Virtual International Stroke Trials Archive Stroke, June 1, 2007; 38(6): 1905 - 1910. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. P. Adams Jr, G. del Zoppo, M. J. Alberts, D. L. Bhatt, L. Brass, A. Furlan, R. L. Grubb, R. T. Higashida, E. C. Jauch, C. Kidwell, et al. Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation, May 22, 2007; 115(20): e478 - e534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. P. Adams Jr, G. del Zoppo, M. J. Alberts, D. L. Bhatt, L. Brass, A. Furlan, R. L. Grubb, R. T. Higashida, E. C. Jauch, C. Kidwell, et al. Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/ American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists Stroke, May 1, 2007; 38(5): 1655 - 1711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fisher, A. Davalos, A. Rogalewski, A. Schneider, E. B. Ringelstein, and W.-R. Schabitz Toward a Multimodal Neuroprotective Treatment of Stroke Stroke, April 1, 2006; 37(4): 1129 - 1136. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bruno, C. Saha, and L. S. Williams Using Change in the National Institutes of Health Stroke Scale to Measure Treatment Effect in Acute Stroke Trials Stroke, March 1, 2006; 37(3): 920 - 921. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Lyden, L. Claesson, S. Havstad, T. Ashwood, and M. Lu Factor Analysis of the National Institutes of Health Stroke Scale in Patients With Large Strokes Arch Neurol, November 1, 2004; 61(11): 1677 - 1680. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. L. Lutsep Current Status of Hemorrhagic Stroke and Acute Nonthrombolytic Ischemic Stroke Treatment Stroke, November 1, 2004; 35(11_suppl_1): 2746 - 2747. [Full Text] [PDF]
|
|
|
|
|
|
C. J. Weir, M. Kaste, K. R. Lees, and for the Glycine Antagonist in Neuroprotection Int Targeting Neuroprotection Clinical Trials to Ischemic Stroke Patients With Potential to Benefit From Therapy Stroke, September 1, 2004; 35(9): 2111 - 2116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. H. Danton and W. D. Dietrich The Search for Neuroprotective Strategies in Stroke AJNR Am. J. Neuroradiol., February 1, 2004; 25(2): 181 - 194. [Full Text] [PDF]
|
|
|
|
 |
|
 B Cucchiara, S E Kasner, D A Wolk, P D Lyden, V A Knappertz, T Ashwood, T Odergren, and A Nordlund Lack of hemispheric dominance for consciousness in acute ischaemic stroke J. Neurol. Neurosurg. Psychiatry, July 1, 2003; 74(7): 889 - 892. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Harmon, E. Coleman, C. Marshall, W. Lan, and G. Shorten The Effect of Clomethiazole on Plasma Concentrations of Interleukin-6, -8, -1{beta}, Tumor Necrosis Factor-{alpha}, and Neutrophil Adhesion Molecule Expression During Experimental Extracorporeal Circulation Anesth. Analg., July 1, 2003; 97(1): 13 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Gladstone, S. E. Black, and A. M. Hakim Toward Wisdom From Failure: Lessons From Neuroprotective Stroke Trials and New Therapeutic Directions Stroke, August 1, 2002; 33(8): 2123 - 2136. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Lyden, A. Shuaib, K. Ng, K. Levin, R.P. Atkinson, A. Rajput, L. Wechsler, T. Ashwood, L. Claesson, T. Odergren, et al. Clomethiazole Acute Stroke Study in Ischemic Stroke (CLASS-I): Final Results * Editorial Comment: Final Results Stroke, January 1, 2002; 33(1): 122 - 129. [Abstract] [Full Text] [PDF]
|
|